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Extensive psoriasis in 1,308 patients has been treated two or three times a week with oral 
-methoxypsoralen followed by high intensity, long-wave ultraviolet light (PUVA I. Exclud-
mg 169 patients still under early treatment, psoriasis cleared in 88'« and failed to clear in 
3%. One percent dropped out due to complications of t reatment. and % for other reasons. 
The twice-a-week schedule was superior for patients with lighter skin types. Once a 
remission was induced, there was no difle rence in its mamtcnance when patients were 
treated once a week, once every other week. or once every third week. Each of these 
schedules was superior to no maintenance treatment. Immediate s ide effects of the 45.000 
treatments administered in the first 1 months of this study were uncommon. temporary, 
and generally mild. No clinically significant changes in laboratory screening or eye exami-
nations attributable to PUV A have been uncovered. 
In December, L974 , the lu-st report was pub-
lished on the use of ora l 8-methoxypsoralen fc>l-
lowed by high-intensity, long-wave ultraviolet. 
I ight ( UV A, 320 nm I for the treatment of psoriasis 
Ill. The treatment is known as PUV A (psoralen 
plus UVAJ. In July, 1975. a randomized coopera-
ti ve clinical trial was initiated among 16 centers 1n 
the United States to investigate the safety and 
eflicacy of various PUV A treatment schedules. 
This report is based on data obtained by the partic-
ipating investigators on 45.000 treatments admin-
istered to 1,308 patients during the fi rst 18 month 
of this ongoing study. !The participating investi-
gators, the centers, and the number of patients 
from each center are listed in Appendix l.l 
PUV A is an experimental tech nique>, not yet 
approved by the Food and Drug Adminis tration. 
that. has been used to induce and maintain a tem-
pora ry remission of psoriasis. ln the present s tudy, 
each of the 16 centers was asked to enter 50 or 
more patients with at least 30'k of their body 
affected by psoriasis at the time of the first. treat-
ment. Afte r 50 such patients were entered, pa-
This study was supported by a grant to the coopera-
tive ccnt.ers from the GTE Sylvania Lighting Products 
Group and by a grant ( HS 001881 to the Beth lsral.'l 
Hospital from the National Center for Health Services 
Research. 
" The participating investigators are list.ed in Ap-
pendix 1. 
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tients with Jess involvement c:ould be mcluded. 
Exclusions for entry wen· pregnancy. aphakia. usP 
of systemic cytotoxic agents with1n a month of the 
first treatment. and use of top1cal medications 
other than emol llent.s for a rea, otht•r than the 
sralp. inlertngmous regions. or soles ur f(•et. 
METHODS 
8-Met.hoxypsnralen was provided 1n 10-mg cap-
sules and administ.ct·cd according to tlw schedule 
in Appendix 2. Special UVA l1ghl box treatnwnt 
systems developed and prepared by the GTE Syl-
vania Lighting Products Group, Danvers, Ma s. 
were used 121. UVA treatments were g1ven 2 to 3 
hr after ingestion of 8-methoxypsoralt•n <Oxsalen. 
provided by the Paul B. Elder Company. Bryan. 
Ohiol. Patients were completely d1srobed and 
sl.ood 1n th<.• l1ght box during UVA exposure. They 
wore goggles during treatment and were in-
structed to wear sunglasses for tlw remainde r of 
the day. Treatments were admin1st.cred by trained 
technicians and 1·anged from IPss than 1 min lo 
more than 1 hr. 
The exposure < m Joules/em~) for the fi rst treat-
ment was based on skin type. a gradl'd estimate of 
sun tolerance and facu ltative tanning dett'l'mmcd 
from history a nd racial extractwn <Appendix 3J. 
Since therapc•utic results on the extremities 
lagged behind those on the trunk . tht· protocol 
al lowed for additional expusun· io the extremities, 
beginning with t.he f'irst. t.reatml'nl and increasing 
to 1/ 2 the t.ot.al-body dose. 
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Treatment Schedules for Clearing Psoriasis 
Patients with skin types I- IV were randomized 
to twice-a-week or three-times-a-week treatment 
schedules. The twice-a-week schedule required 72 
or more hr between treatments, and the three-
times-a-week schedule required 48 or more hr. On 
both schedules, the exposures were increased by 
0.5 J/cmt at each treatment, if minimal or no 
erythema from the previous exposure was ob-
served. The treatment response is shown in Ap-
pendix 4. Jf a definite improvement (grade 2 treat-
ment response) by the 6th treatment or a marked 
Improvement (grade 3 response) by the 9th treat-
ment was not achieved, the patient was considered 
a "slow responder" and was changed to an acceler-
ated schedu le. For patients on the three-times-a-
week schedule, acceleration meant increasing ex-
posure by 1.0 J/cm~ at each treatment. For those 
on the twice-a-week schedule, acceleration meant 
randomization to either the accelerated three-
times-a-week schedule or to a twice-a-week sched-
ule in which exposure was increased by 1.5 Jlcmt 
at each treatment. 
Randomization was accomplished by a computc1· 
routine that selected the appropriate schedules 
and printed them on the last page of the original 
patient questionnaire. Equal numbers of patients 
in each study arm were intended. 
Patients with skin types V and VJ were not 
random1zed and were all assigned to the three-
limes-a-week schedule. In addition, their expo-
sures could be increased at each lreatment up to 
1.5 J/cm~ if they were slov. responders and were 
placed on the accelerated schedule. 
Trm/nwnl Sclwclull'.'i /c1r Mainll•nann• of' 
R 1'111 1ssion 
Patients W(•rp placed on mamtenance when 
thc1r condition was 95/k improved. It became ap-
pan•nt that clt•aring was defined differently in the 
various centers and that a patient whose psoriasis 
had "cleared'' might havt• macular e1ythema, ma-
cular hypcrpigmt>ntation. or normal skin . The def-
inition was assumed to be un1formly applied 
within each center. Failure to clear by the 30th 
treatment was considered a treatment failure and 
allowed the centt•r to stop tn·atment.. 
Lf their psonas1s cleared. pat1ents were ran-
domly assigned to one of four maint-enance sched-
ules: one treatment every week. one every other 
week, one every third week. or no treatment until 
a flare occurred. UV A exposure during mainte-
nance remained constant unless erythema or pso-
riasis developed. If erythema developed (due to 
loss of tan), t reatments could be decreased by 0.5 
to I J/cm~. If psoriasis developed. treatments could 
be increased by the same amount in patients with 
a light to m~ium tanning response to previous 
PUVA therapy, by 1 J /cmt in those with a dark 
tanning responst•, or by 1 to 2 J/cm~ in those with 
skin types V and VI. 
Treatment S chedule for Flares During 
Maintenanc:e 
Flare during maintenance was defined as pso-
riasis on 5% or more of the skin. The treatment 
schedule for clearing a flare was three treatments 
per week with an increment of up to 1 J /cm2 at 
each treatment. Patients who had originally 
cleared and then needed three treatments a week 
or four treatments in two weeks were regarded as 
having flared. The starting exposure of UV A for 
clearing a flare was the last maintenance expo-
sure, if the patient had been treated during that 
period, or the original clearing exposure, if there 
had been no treatment during maintenance and 
tan was lost. The t reatment of flares has not been 
analyzed. 
DATA COLLECTION 
Base-line and demographic data were collected 
on a self~administered questionnaire. Side effects 
were recorded at each treatment for approxi-
mately the first 41 ,000 treatments. The laboratory 
data included hematocrit. white blood-cell count, 
differential count and serum concentrations of uric 
acid. bilirubin, a lkaline phosphatase, glutamic ox-
alacetic transaminase, lactic dehydrogenase, urea 
nitrogen, and creatinine. Urinalyses and antinu-
clear antibodies were recorded. The studies were 
performed in local laboratory facilities at each 
center. Laboratory studies were requested ini-
tially and every three months during the first 
year. Complete ophthalmologic examinations 
were required initially, at three months, and at 
one year. Physical examinations were completed 
as needed for management of patients. 
All data were entered into a specially designed, 
on-line data-management system, an earlier ver-
sion of which has been described 131. 
RESULTS 
These results are based on data received by 
December, 1976. The mean age of the 1,308 pa-
tients was 44 years, with a range of 5 to 85 years. 
Sixty-five percent of the patients were male (Ap-
pendix 51, and 56/ff had skin type II1 <Appendix 3). 
Plaque type psoriasis was present in 849t, guttate 
in 12o/c, and erythrodermic in 4%. Only two pa-
tients had pustular psoriasis. The mean duration 
of psoriasis was 19 years, with a range ofless than 
1 year to more than 76. A significant proportion of 
patients had received ystemic therapy; metho-
trexate had been given to 45% and systemic corti-
costeroids to 19% <Appendix 6). The average ex-
tent of skin involvement was 33~. 
Cll!anng Phase 
The treatment response of all patients is shown 
in Table I. Skin type and treatment schedule did 
not appear to have much influence on the response 
to treatment, but type of psoriasis did. In patients 
with plaque or guttate psoriasis, the failure-to-
clear rate was 2%-, a nd the overall dropout rate 
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T~LE I. Results of treating patients with psoriasis 
Results Number of Percent of pa-patients tients 
Psoriasis cleared 
Less than 30 treatments 787 69 
30 or more treatments 218 19 
Dropped out of treatment 
Failed to clear 33 3 
PUV A complications" 14 l 
Other complicationsb 18 2 
Other reasons' 69 ___§_ 
Total 1139 100 
Still under treatment for 169 
clearing psoriasis 
" Five patients with flares of psoriasis (2 with 
plaques. 2 with erythrodermic disease, 1 with pustules), 
2 with burns, 2 with pruritus, 2 with nausea, 1 with 
tanning, 1 with a flare of preexistent bullous pemphe-
goid. and l with claustrophobia. 
b Three cardiovascular deaths (none during a PUVA 
treatment), 1 with cardiovascular disease, 4 with gas-
trointestinal disorders (2 with diarrhea. 2 unspecified). 
2 with depression, 2 with alcoholism, 1 with artht-itis, 1 
with a positive ANA, and 1 with eye surgery. 
' Principally transportation and expense. 
was 9o/c. Of those with erythrodennic psoriasis, 
l6 o/c failed to clear, and 29% dropped out (p < 0.01 
by chi-square analysis of a contingency table com-
paring the three types of psoriasis with clearing. 
failure to clear, or dropping out). 
The requirements for clearing that we have cal-
culated include the total J /cm2 (excluding extra 
doses to arms and legs>. the total number of treat-
ments, the J /cm2 given at the last clearing treat-
ment, and the elapsed time in weeks. These data 
are shown as a function of skin type and type of 
psoriasis in Tables II and Ill. The results indicate 
that more total J/cm~ and more J/cm~ at last-
clearing-treatment were required to clear the 
more sun-tolerant skin types. In addition. more 
total J /cm2 , more treatments, and more weeks of 
treatment were required to clear erythrodermic 
psoriasis than plaque psoriasis, and more were 
required to clear plaque than guttate psoriasis. 
The analysis of requirements for clearing as a 
function of treatment schedules was complicated 
by changes of schedules in violation of protocol , by 
gaps in clearing treatments, and by extra clearing 
treatments. To improve the analysis. data on some 
patients were excluded. Randomly assigned clear-
ing schedules were changed in 170 patients. In 136, 
a three-times-a-week schedule was switched to a 
twice-a-week schedule, indicating a strong patient 
and/or provider preference for this schedule. Two 
centers accounted for 26% of all schedules 
switched, and all patients from these centers were 
excluded from the comparative analysis of clear-
ing schedules. 
A gap in the clearing phase was defined as 
either two missed treatments in one week or one 
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missed treatment in each of two consecutive 
weeks. The majority of gaps did not appear to 
result from PUV A toxicity, and therefore all pa-
tients with one or more gaps were excluded from 
the comparative analysis of clearing. Patients who 
received extra clearing treatments were excluded. 
Patients with skin types V and VI were not as-
signed to the twice-a-week clearing schedule and 
were also excluded. 
The dearing requirements of selected cases 
(after exclusions) are shown in Table IV. Patients 
with a twice-a-week schedule required less total J / 
cm1 and fewer treatments, but more time, to 
achieve clearing. However , when these data are 
analyzed by skin types. the trends are reversed for 
patients with skin type IV. 
The probability of achieving clearing as a func-
tion of the number of treatments is shown in Fig-
ure l. The curves were constructed with life-table 
techniques [5,6). Dropouts due to medical or 
PUV A complications were treated as failures. and 
dropouts for other reasons were treated as with-
drawals from the study. All cases. selected cases 
on a twice-a-week schedule and selected cases on a 
three-times-a-week schedule, are shown. Also 
shown is the 95~ confidence band for all selected 
cases. It is concluded from this analysis that gaps 
increase the number of treatments required and 
decrease the overall clearing rate a nd that pa-
tients on the twice-a-week schedule require fewer 
treatments to achieve clearing. After exclusions. 
the number of patients was too small to permit 
firm conclusions about the accelerated schedules. 
but the twice-a-week schedule again appeared to 
require fewer J /cm1 and fewer treatments. 
Maintenan('e Phase 
Table V shows the mamtenance status, as of 
December. 1976, for the 1.005 patients whose pso-
riasis cleared. The chance of a flare was not influ-
enced by skin type. but was by type of psonasis. 
Flares had occurred in approximat.ely 35% of pa-
tients with guttate or plaque type psoriasis and in 
58% of those with erythrodermic psoriasis (p < .01 
by chi-square analysis for a contingency table with 
three types of psoriasis vs flared or not flared 14]). 
The maintenance schedule also influenced flaring. 
Sixty-two percent of the patients on the no-treat-
ment schedule had flares compared to 27. 30, and 
34% of the patients on the once-a-week, once-ev-
ery-two-weeks, and once-every-three-weeks sched-
ules, respectively (p < .05 by chi-square analysis 
for a contingency table with four maintenance 
schedules vs flared or not flared [4]). Differences 
between the schedules excluding the no-treatment 
schedule were not statistically significant. 
The probability of remaining clear of psonasis 
for each test, and extreme results on last compared 
no-treatment schedule resulted in more flares 
sooner. The differences between the other sched-
ules are small. 
The patients excluded from the comparative 
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TABLE II . R equirements for clearing psoriasis by skin type" 
Skin type (no. of pa- Mean total J /cm• Mean no. of treatments Mean no. of weeks Mean J/cm2 at last tientsJ clearing t reatment 
I (48) 191 23.6 12.5 9.6 
II (214) 187 21.7 11.0 12.3 
III (571) 253 23.6 11.6 14.4 
IV (126) 296 24.2 12.3 16.4 
v (17) 410 31.7 15.9 19.2 
VI (16) 469 22.4 9.6 21.1 
p < .01 n .s. (p > .05) n .s. (p > .05) p < .01 
" Based on the mean values of 992 of 1,005 patien ts who cleared and for whom complete data were available. P-
values for column trends a re for one-way analyses of variance for unequal sample s1zes 14). 
TABLE III. R equirements for dearing psoriasis by type of psoriasis" 
Type of psoriasis (no. of patienUi J Mean total J /cm2 Mean no. of treat- Mean no. of weeks Mean J /cm• at last clearing ments t reatment 
Guttate fl22) 208 20.3 9.8 13.2 
Plaque (831 l 251 23.6 ll.8 14.3 
Erythrodermic (25) 368 31.6 16.4 13.2 
p < .05 p < .01 p < .01 n .s. (p > .051 
" Based on the mean values of 978 of 1,005 patients who cleared a nd for whom complete data were available. P-
values for column trends are for one-way analyses of vanance for unequal sample sizes 14). 
TABLE IV. Requirements for t learing psorias1s: comparison of tu·1ce-a-week us three-times-a-week treatment 
schedules'' 
Mean J/cm' at 
Skin types PUV A treatments per 
week (no. of patienUi I Mean total J /cm" Mean ~~n~ treat- Mean no. of weeks last clearing treatment 
Two tl5) 93 17.1 9.5 8.8 
Three 18J 131 18.3 7.1 8.1 
II Two <541 150 17.7 9.5 0 12.8 Three t53) 152 18.8 7.lp <. l 11.9 
lll Two (1531 172 p < .01 18.2 0 9.6 0 13.4 Three (138) 226 21.4 p < . 1 .0 p < . 1 14.9 
IV Two t27 J 266 21.0 10.9 0 16.1 Three <331 193 18.4 6.9 p < .I 14.6 
I. II. ITI, & IV Two \249) 173 0_ 1 .3 9.7 13.3 Three (2321 201 p < . :> 20.3 p < ·01 7.6p < .Ol 14.0 
" Based on mean va lues of 481 of 1.005 patien ts who cleared for whom complete data were available and the 
exclusion criter ia in the text were satisfied . P-values for differences are for one-way analyses of variance for 
unequal samples sizes 14]. P-values greater than .05 not shown. 
analysis of maintenance schedules were those 
with more than or:e gap in maintenance per 10-
week period. those with more than one extra treat-
ment per 10-week period, and those whose mainte-
nance treatment schedule could not be classified . 
A gap in maintenance was defined as one mainte-
na nce treatment two weeks late or two successive 
maintenance treatments one week late. Protocol 
was violated by changing maintenance schedules 
in 169 patien ts; since these patients were uni-
formly distributed across centers. no center was 
eliminated from analysis. A switch to the once-a-
week schedule accounted for 109 of the 169 sched-
ules changed. 
A cute Side Effects 
Acute side effects <erythema, nausea. pruritus. 
headache, and dizziness! were rare in the 41 .000 
treatments analyzed. The results in Table VI are 
expressed as a percentage of treatments, rather 
than a percentage of patients. Erythema was eval-
uated by the technicians before each treatment. 
The incidence of nausea. pruritus, headache. and 
dizziness are based on patients' responses to ques-
tionnaires. Trimethobenzamide hydrochloride was 
infrequently given for nausea. and reported to be 
helpful about a third of the time. Emollients were 
given for pruritus 82% of the times it was reported 
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FIG. 1. Probability of patients having psoriasis as a 
function of the number of clearing treatments. Selected 
cases of treatment schedules are shown, as well as the 
95% confidence band for all selected cases. The curve for 
all cases without exclusion is also shown. 
TABLE V. Current status o(th.e 1.005 patients cleared of 
psoriasis 
Status Number of Percent of pa-pat.ients tients 
Psoriasis still clear 580 57.6 
Psoriasis flared. retreated 356 35.4 
Dropped out of treatment 
PUV A complications" 1 .1 
Other complications• 6 .7 
Other reasons' 62 6.2 
1,005 100.0 
" Erythema multi forme r esponse to psoralen without 
UVA. 
• One patient died from myocardial infarction, and 1 
from aspiration and alcohol abuse. One patient dropped 
out with metastatic breast carcinoma, l with syncope 
several days after last PUV A t reatment, 1 with rheu-
matoid arthritis, and 1 with myocardial infarction. 
,. Principally transportation and expense. 
and were helpful 64% of the time. Antihistamines 
were used for pruritus 31 o/c of the times it was 
reported and were helpful 68% of the time. 
Erythema of any degree for patients with skin 
types I-VI was r eported 5.0, 3.9, 3.7, 1.7, 1.4, a nd 
1.1% of treatments, respectively (p < .05 l:ly one-
way analysis of variance for unequal sample sizes 
14]). This is an expected trend for increasing pig-
mentation. The relationship between treatment 
schedule and erythema is still being investigated. 
However, preliminary analysis shows fewer re-
ported instances of erythema in patients on the 
twice-a-week schedule, perhaps because the ery-
thema from PUV A generally peaks at 48 hr, and is 
therefore more likely to be observed on the three-
times-a-week treatment schedule. 
Analysis of Laboratory Data 
Analysis of the laboratory data was complicated 
because each center used its own laboratory meth-
ods and normal ranges. One center changed the 
method of LDH determination during the study, 
and these data were deleted from the analysis. If 
the mean and standard deviation of a normal pop-
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ulation were known for each test for each center, 
results could have been converted to standard 
scores and analyzed together. Since s uch data are 
not available, they were estimated by computing 
the means and standard deviations of the initial 
values for each test at each center. The 10% most 
extreme initial results for each test at each center 
were not used in these computations, so that the 
values were not skewed by known deviant. pa-
tients. All laboratory data were analyzed subse-
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F1G. 2. Probability of remaining clear of psoriasis as 
a function of weeks on maintenance. Four maintenance 
schedules are shown as well as the 95'* confidence band 
for all cases collectively. 
TABLE VI. I mmedwte side e/l(•cts af~er PUV A " 
Side effect 
Erythema/Burns- local or diffuse, 
grade 
Localized edema or blistering 
Diffuse marked red or edema 
Caused missed treatment 
Nausea After Last Treatment 
Interfered with activity 
At least 12 hr duration 
With vomiting 
Caused missed treatment 
Pruritus 
Generalized 
lnterfered with sleep 
For more than 3 days 
Interfered with activity 
Caused missed treatment 
Headache 
Continuous 
Interfered with activity 
At least 24 hr duration 
Caused missed treatment 
Dizziness 
Continuous 
Interfered with activity 
At least 8 hr duration 
Caused missed treatment 
Percent of 
treatments 
any 9.77 
.24 
1.12 
1.15 
3.21 
.64 
.37 
.30 
.08 
14.08 
6.43 
5.13 
5.02 
l. 74 
.44 
2.00 
1.25 
.36 
.21 
.02 
1.52 
.74 
.38 
.29 
.02 
" Side effects expressed as a percentage of t reat-
ments. Neither the major categories nor the subcatego-
ries are mutually exclusive. For example. one episode 
of nausea may cause a missed treatment, result in 
vomiting, last for more than 12 hr, and interfere with 
activities. 
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TABLE VII. Analysis of last minus first laboratory results 
Number with Number with Number with P-value by sign P-value by Stu-Test positive negative Mean change" 
change no change change test dent's 1-test 
He matocrit 422 133 363 < .05 +.27 <.01 
WBC 396 31 494 < .01 - .16 <.01 
Bilirubin 359 138 414 < .1 -.005 >.2 
Alkaline phosphatase 392 59 463 < .05 - 4.83 < .001 
SGOT 411 70 436 > .2 -1.06 <.1 
LDH 350 32 445 < .001 -5.15 < .01 
BUN 400 86 269 < .001 +.79 <.001 
Creatinine 370 193 302 < .01 +.01 <.1 
Uric acid 367 47 498 < .001 -.16 < .001 
" Mean changes expres;sed in the laboratory units of a representativE" center. Standard deviations for alkaline 
phosphatase, SGOT. and LDH in this center were estimated at 17.8, 7.3, and 30.6, respectively. 
quently as standard scores. Two types of a na lyses 
were used: last minus first results for each patient 
for each test, and extreme results on last compared 
to first determinations. 
The mean elapsed time from the {irst treatment 
Lo the last laboratory determination was six 
months. The anaJysis of'last minus first laboratory 
results is given in Table VII. HCT and BUN in-
creased significantly (p < .05!, and WBC, alkaline 
phosphatase, SGOT, LDH, and uric acid de-
creased. An upward trend in creatinine was statis-
tically significant by the sign test but not by Stu-
dent's t-test. The magnitude of a ll mean changes 
was clinically trivial. 
An extreme final result was defined as a value 
that was 2 standard deviations beyond the mean 
and that had worsened 1 standard deviation from 
the initial value. An extreme initial result was 
defined as a value that was 2 standard deviations 
beyond the mean and that had improved by 1 
standard deviation at the time of the final value. 
The number of patients with an extreme final 
result was compared to the number with an ex-
t reme initial result (Table Vlll l. Each patient 
with a n extreme final result was carefully re-
viewed, and none has been dropped from treat-
ment because of impairment of kidney, liver. or 
hematopoietic function attributable to PUV A. 
Small changes in laboratory values may be arti-
facts introduced by serial determinations and in-
adequate standardization. Analysis of first and 
last laboratory values (excluding uric acidl from 
approximately 300 additional patients receivi ng 
PUV A at the Masschusetts General Hospital re-
vealed statistically significant changes of the op-
posite direction for hematocri t , bilirubin , LDH, 
and creatinine and failed to substantiate a de-
crease in alkaline phosphatase (E. Gonzales, un-
published datal. No clinically significant abnor-
mal laboratory findings attributable to PUV A 
have been made. 
Analysis of' Ophthalmologic Examinations 
The ophthalmologic evaluation consisted of 
gross examination. acuity, slit lamp. and fundu-
scopic tests. The results were classified as normal 
TABLE Vlll. Analysis of extreme laboratory results" 
Patients Patients Probability 
with ex- with ex-Test treme ini- treme final value by 
tial results results sign t.est 
Low hematocrit 19 10 >.1 
Low WBC 9 3 > .1 
High WBC 57 31 < .05 
High uric acid 36 20 < .05 
High bilirubin 70 78 > .2 
High alkaline 55 46 > .2 
phosphatase 
High SGOT 75 71 > .2 
H igh LDH 51 45 > .2 
High BUN 30 81 < .001 
H igh creatinine 39 57 < .05 
" Extreme result was defined as greater than or 
equal to 2 SD beyond the mean and greater than or 
equal to 1 SD change over time. 
TABLE IX . Abn, rmal e_ve exams" 
First Last 
Acuity 44 42 
Slit lamp 46 37 
Fundoscopic 41 34 
Gross 27 18 
" Abnormal eye exams as defined by the ophthalmol-
ogist on either the first or last examination but not 
both. These dala are based on 655 patients. 
or abnormal according to the criteria of the exam-
ining ophthaJmologist. Patients abnormal on the 
last examination but normal on the first were 
compared to patients abnormal on the first exami-
nation but normal on the last.. The mean time 
elapsed from the first treatment to the last eye 
examination was 4.5 months. and 655 patients had 
follow-up examinations. The analysis of abnormal 
eye examinations is given in Table IX. No statisti-
cally significant changes were noted. 
DISCUSSION 
Thirteen hundred and eight patients with exten-
sive and long-standing psoriasis have been treated 
with a new modality with encouraging results. 
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Short-term side effects seldom interrupted ther-
apy. Although long-term toxicity remains un-
known to date, no such effects have been uncov-
ered. The increases in BUN and creatinine have 
not been clinically significant and are of uncertain 
etiology. Improved nitrogen consumption or a ne-
phrotoxic effect of psoraJen can be postulated. No 
cases of renal insufficiency have been found. 
Control groups of psoriatic patients using other 
forms of therapy have not been studied, and the 
benefits of PUV A as compared to those of other 
forms of therapy rema in uncertain. Since meth-
oxsaJen dosage, UV A dosage, light source, t reat-
ment schedule, and concomitant therapy may vary 
enormously, these data cannot be extrapolated to 
other protocols. 
The twice-a-week treatment schedule seems 
preferable to three-times-a-week for skin types I, 
II, and III because it requires less total J/cm~ and 
fewer treatments for clearing and less J/cm~ at 
maintenance. Better results of the three-times-a-
week schedule for skin type IV probably reflect the 
interference of tanning. In theory, larger incre-
ments in UVA or psoralen dosage could compen-
sate for tanning. However , the exposure time re-
quired with the present UV A system limits the 
dose that can be delivered. Treatments that last 
more than 30 mins are poorly tolerated because of 
heat and orthostatic stresses. Heart rates in excess 
of 100 and minor arrythmias have been observed 
(A. Rhodes and R. Ciafone, unpublished data). 
Increases in methoxsalen dosage result in a 
higher incidence of nausea. Remissions induced by 
PUV A are temporary; once-a-week maintenance 
treatments did not prevent 50% of patients from 
flaring by 1 year. 
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The rigid maintenance schedules attempted in 
this study are unlikely to be used in practice. 
Patients are not apt to wait until there is signifi-
cant flare in psoriasis before requesting additional 
therapy. Facial , hand, foot, and genital involve-
ment are particularly distressing, and it may not 
be appropriate to use this totaJ-body treatment to 
clear limited areas of psoriasis, which may appear 
or remain stable during the maintenance period. 
The risks, costs, and benefits of PUV A in the 
treatment of psoriasis in aJI its variations and 
degrees are not yet defmed. However , efficacy for 
extensive and refractory types of psoriasis has 
been established , and major toxicity has not been 
found. 
The authors wish to t hank the patients and P UV A 
technicians who made this study possible. 
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App('ndu: 4. Treatment Response 
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